Compare
Skyrizi vs. Bimzelx

Skyrizi (risankizumab or risankizumab-rzaa) is an injection used to treat different inflammatory conditions in adults. This includes plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It belongs to the drug class called interleukin antagonists. It works to lower inflammation and relieve symptoms. After the first few doses, you usually get the Skyrizi (risankizumab) injection every 2 or 3 months. This medication can raise your risk of infection as a side effect.

• Moderate-to-severe plaque psoriasis in adults
• Psoriatic arthritis in adults
• Moderate-to-severe Crohn's disease in adults
• Moderate-to-severe ulcerative colitis in adults

• Upper respiratory infections (13%)
• Headache (4%)
• Tiredness (3%)

• Allergic reaction
• Risk of infection
• Rare case of liver injury
• Caution when getting vaccines

Bimzelx (bimekizumab or bimekizumab-bkzx) is an injection that's used to treat several inflammatory conditions in adults. They include plaque psoriasis, psoriatic arthritis, and hidradenitis suppurativa, to name a few. It's a type of monoclonal antibody called an interleukin antagonist. It works to reduce inflammation in the body. Bimzelx (bimekizumab) comes in prefilled autoinjectors or prefilled syringes. You inject the medication under the skin either every month or every other month. It can cause side effects like upper respiratory infections.

• Moderate-to-severe plaque psoriasis
• Psoriatic arthritis
• Non-radiographic axial spondyloarthritis
• Ankylosing spondylitis
• Moderate-to-severe hidradenitis suppurativa

• Upper respiratory tract infection (runny nose, sore throat; 15%)
• Oral thrush (9%)
• Headache (3%)
• Injection site reactions (redness, pain, swelling, bruising; 3%)
• Fungal skin infections (3%)

• Suicidal thoughts or behavior
• Risk of infections
• Liver problems
• Inflammatory bowel disease
• Interaction with vaccines